OPTIVATE 100 IU/ML A POWDER FOR SOLUTION FOR INJECTION
Active substance(s): HUMAN FACTOR VIII / VON WILLEBRAND FACTOR
OPTIVATE® 250 IU, 500 IU, 1000 IU
POWDER FOR SOLUTION FOR INJECTION
HIGH PURITY FACTOR VIII AND VON WILLEBRAND FACTOR CONCENTRATE
Please read all of this leaflet carefully before you start using this medicine.
• Keep this leaflet you may need to read it again.
• If you have any further questions, please ask your doctor.
• This medicine has been prescribed for you personally. Do not pass it on to others. It may harm them, even if their symptoms are the
same as yours.
• If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor.
In this leaflet:
1. What Optivate is and what it is used for
2. Before you use Optivate
3. How to use Optivate
4. Possible side effects
5. How to store Optivate
6. Further information
1. WHAT OPTIVATE IS AND WHAT IT IS USED FOR
Optivate is a high purity factor VIII and von Willebrand Factor concentrate from human blood plasma obtained from screened donors.
It is a white sterile powder, supplied with sterile water (Sterilised Water for Injections, Ph.Eur.). Optivate is given by injection into a vein
(intravenously) and is used to prevent and treat bleeding in patients with Haemophilia A (congenital factor VIII deficiency in the blood).
Your doctor will explain further why this medicine has been given to you.
2. BEFORE YOU USE OPTIVATE
Do not use this medicine and speak to your doctor if you think you could be allergic (hypersensitive) to the active substance(s) or to
any of the other ingredients (See section 6 for a list of these).
• Your doctor will advise you as to which vaccinations you should be given as a routine precaution, because you are receiving a blood
• If you have a larger or longer bleed than usual and the bleeding does not stop after an injection of Optivate, speak to your doctor.
Some patients with a shortage of factor VIII may develop inhibitors (antibodies) to factor VIII during treatment. This could mean that
the treatment will not work properly. Your doctor will check regularly for the development of these antibodies, and especially before
Both before and after treatment with this medicine, particularly for your first course of treatment, your doctor will probably carry out
tests to check the level of factor VIII in your blood.
• This medicine may contain small amounts of blood group antibodies originally present in the plasma from the donors. This is normal
and, in most cases, these antibodies do not cause any problems. However, if you need large doses of Optivate, for example during
surgery, and are blood group A, B, or AB, your doctor may need to do a blood test to check if the medicine has had any effect on your
red blood cells.
Taking other medicines
These injections must not be mixed with other medicinal products in the same syringe.
Please tell your doctor if you are taking or have recently taken any other medicines, including medicines obtained without a
Pregnancy and breast-feeding
If you are pregnant, think you may be pregnant or are breast-feeding, tell your doctor. Your doctor will tell you if this product is
necessary for you to take at this time.
Driving and using machines
There are no known effects of this product on the ability to drive or operate machinery.
When medicines are made from human blood or plasma, certain measures are put in place to prevent infections being passed on to
patients. These include careful selection of blood and plasma donors to make sure those at risk of carrying infections are excluded, and
the testing of each donation and pools of plasma for signs of virus/infections. Manufacturers of these products also include steps in the
processing of the blood or plasma that can inactivate or remove viruses. Despite these measures, when medicines prepared from human
blood or plasma are administered, the possibility of passing on infection cannot be totally excluded. This also applies to any unknown
or emerging viruses or other types of infections.
The measures taken are considered effective for enveloped viruses such as human immunodeficiency virus (HIV), hepatitis B virus and
hepatitis C virus and for the non-enveloped hepatitis A and parvovirus B19 viruses.
It is strongly recommended that every time you receive a dose of Optivate, the name and batch number of the product are recorded in
order to maintain a record of the batches used.
1627 Optivate PIL UK 3.indd 1
Colours: Pantone Process Black
3. HOW TO USE OPTIVATE
Before injecting this medicine at home, you will have received training at your Haemophilia Centre on how to do so.
Use only the recommended injection equipment provided with your medicine.
How much Optivate to give
Always use this medicine exactly how your doctor has told you. You should check with your doctor if you are not sure.
• Your doctor will explain to you how much you should use and when you should use it.
• Your doctor will usually tell you your dose in terms of the number of full vials nearest to the dose most suited to you.
• If further treatment is needed, doses may be repeated at intervals of 8, 12 or 24 hours, as required. Your doctor will advise you if this
The table gives the approximate doses of factor VIII which are needed to stop bleeding in various conditions:
Initial dose of Optivate
(IU/kg body weight)
Minor spontaneous bleeding in joints and muscles.
8 – 16
Severe bleeding in joints and muscles, haematoma
(swelling caused by collection of blood) in potentially
serious situations, blood in the urine.
12 – 24
How much do adults require to prevent bleeding?
20 to 40 IU/kg every 2 or 3 days is usually enough.
For children under the age of 6 years, your doctor will recommend the appropriate dose but the usual dose is 17 to 30 IU/kg. This can
be given up to 3 times a week for prevention of bleeding.
When to inject Optivate
• The medicine should be injected when the first sign of bleeding occurs.
• The injection should be repeated as necessary to stop the bleeding.
• Each individual bleed should be judged on its own severity.
• If you are using this product for the first time, your doctor will supervise you.
Dissolving your medicine before use
Your medicine must only be dissolved in the sterile water provided with the product.
Quantity of Optivate
Quantity of Water
1. Before you remove the “flip-off ” top, make sure that the vial of Optivate and the container of water supplied with it are both at room
temperature (between 20°C and 30°C).
2. Sterile water for use with Optivate is provided in an ampoule with a “snap-off ” cap or a glass vial with a stopper.
3. Keep all injection equipment sterile.
4. Do not use any solution if any small bits can be seen in the vials.
There are two ways of continuing to make up the Optivate for injection by the use of a filter needle or Mix2Vial device – only one of
these options will be provided in your pack. Ensure the correct method below is utilised for the transfer device supplied:
Using the Filter Needle (where supplied):
1. If the Water for Injections is in a plastic ampoule, break open the top and draw up the volume of water needed with a sterile needle
and syringe (not the filter needle).
2. If the Water for Injections is in a glass vial remove the “flip-off ” top and clean the top of the stopper with an alcohol swab.
3. If using a double spiked needle (only for use with the correct volume of water for injection in glass vials), remove the cover guard
from one end of the double-ended transfer needle (which your doctor can provide) and insert the needle through the stopper into the
vial of water.
4. Remove the other end of the needle guard, turn it upside down over the vial of Optivate and push the needle through the Optivate
1627 Optivate PIL UK 3.indd 2
Colours: Pantone Process Black Pantone 273
5. On piercing the stopper of the Optivate vial, the water will be drawn in as the vial is sealed under vacuum. A small amount of water
will remain in the water vial, which can be discarded. Continue from point 8 below
6. If using a transfer needle, transfer the water to the vial of Optivate by pushing the needle through the stopper of the vial. The water
in the syringe will be drawn into the vial, which is under vacuum, so there is no need to push the plunger of the syringe. Note: The
filter needle provided must not be used to draw up the Water for Injections.
7. Gently swirl the Optivate vial (do not shake) and then remove the syringe from the needle to release the vacuum in the vial.
8. Continue to swirl the Optivate vial gently until the powder is dissolved (usually in about 2 to 21/2 minutes).
9. When dissolved, draw up the solution using the filter needle attached to a syringe. Use a new filter needle for each vial of Optivate if
your dose is more than one vial.
10. Disconnect the filter needle from the syringe.
11. The product is now ready for administration. Follow the normal safety practices for administration. Use the product immediately
after reconstitution, the product must not be stored.
Using the Mix2Vial (where supplied):
The Mix2VialTM Transfer Device is provided with your product for needle-free, easy and safe use.
The reconstitution is performed as follows:
• Remove the cap from the product
vial and clean the top of the
stopper with an alcohol swab.
• Repeat this step with the sterile
• Peel back the top of the Transfer
Device package but leave the
device in the package.
• The sterile water will be pulled
into the product vial by the
vacuum contained within it.
• Gently swirl the vial to make sure
the product is thoroughly mixed.
Do not shake the vial.
• A clear or slightly pearl-like
solution should be obtained,
usually in about 2 to 21/2 minutes
(5 minutes maximum).
• Place the blue end of the Transfer
Device on the water vial and push
straight down until the spike
penetrates the rubber stopper and
snaps into place.
• Remove the plastic outer
packaging from the Transfer
Device and discard it, taking care
not to touch the exposed end of
• Separate the empty water vial and
blue part from the clear part by
• Draw air into the syringe by
pulling the plunger to the
required volume of water added.
• Connect the syringe to the clear
part of the Mix2VialTM.
• Push the air in the syringe into
• Turn the water vial upside down
with the device still attached.
• Place the clear end of the
Transfer Device on the product
vial and push straight down until
the spike penetrates the rubber
stopper and snaps into place.
• Immediately invert the vial of
solution which will be drawn into
• Disconnect the filled syringe from
• The product is now ready for
administration. Follow the
normal safety practices for
• Use the product immediately
after reconstitution, the product
must not be stored.
Note: If you have to use more than one vial to make up your required dose, repeat Steps 1 to 6 withdrawing the solution in the vial into
the same syringe. The Transfer Device supplied with your product is sterile and cannot be used more than once. When the reconstitution
process is complete dispose of in your ‘sharps box’.
1627 Optivate PIL UK 3.indd 3
Colours: Pantone Process Black
Do not use this medicine if:
• the water is not pulled into the product vial (this indicates a loss of vacuum in the vial, so the product must not be used).
• the dissolved product and Sterilised Water for Injections forms a gel or a clot (if this happens, please tell Bio Products Laboratory
Limited, reporting the batch number printed on the vial). Do not use solutions which are cloudy or have bits in them.
Injecting the medicine
After the medicine is dissolved inject the medicine and attach a suitable needle to the syringe.
The dose, especially your first, should be given slowly (no more than 3 mL per minute) into your vein.
– the solution must not be stored after reconstitution.
– you must finish injecting the dose into a vein within one hour of dissolving the medicine.
– the solution must not be added to any other fluids, blood or any other medicine.
– you should only use the sterile water supplied to make up the solution. Never inject the water on its own, without first dissolving the
powder in it.
How much is given before, during and after major surgery?
Major surgery should only be performed when levels of factor VIII can be tested.
Your blood should be tested for factor VIII inhibitors (antibodies).
If antibodies are not present, a dose of 32 to 40 IU per kg of body weight is given before the operation.
During the first few days after the operation, the plasma factor VIII concentration is usually checked at regular periods.
A dose of Optivate is usually given every 8 to 24 hours, as needed.
After the first few days, the number of times the dose is given may be reduced.
Treatment will be continued for as long as recommended by your doctor.
If the factor VIII concentration does not reach the expected level (this will be tested by your doctor), or if it decreases quicker than
expected (within 12 hours), an inhibitor to factor VIII may be present, which stops factor VIII from working properly. Your doctor is
likely to have the appropriate laboratory tests done to see if there is such an inhibitor present.
If you use more Optivate than you should
If you think you may be using too much, stop the injection and tell your doctor. If you know you have used too much, tell your doctor as
soon as possible.
If you forget to use Optivate
Do not use a double dose to make up for a forgotten dose. Inject your normal dose as soon as you remember and then continue as
instructed by your doctor or Haemophilia nurse.
If you stop using Optivate
Always consult your doctor before deciding to stop your treatment.
4. POSSIBLE SIDE EFFECTS
Like all medicines, Optivate can cause side effects, although not everybody gets them.
Stop the infusion and tell your doctor immediately or go to the emergency department of your nearest hospital, if you get any of the
• Swelling around the throat
• Feeling lightheaded or dizzy (low blood pressure)
• Rapid heart beat
• Hives (nettle rash)
These symptoms may worsen into severe shock. The above allergic-type reactions are very rare (fewer than 1 patient in every 10,000
patients treated get them).
• Feeling sick or being sick
• Tightness in the chest or wheezing
• Tingling sensation
1627 Optivate PIL UK 3.indd 4
Colours: Pantone Process Black Pantone 273 Pantone 430
Other known side effects are:
Adults and Children
Common (more than 1 in every 100 patients treated):
• Other skin rashes
• Feeling that everything is moving, spinning round or tilting (vertigo)
• Redness of the skin (rashes) or pain at the
place where the medicine was injected
• Swelling in the extremities of the body
• Raised temperature (fever)
• Sudden shivering and feeling cold and rapid rise in temperature
• Stiffness in muscles and joints
• Sleepiness, lethargy or feeling unwell
5. HOW TO STORE OPTIVATE
• Keep out of the reach and sight of children.
• You should store the powder in its container and carton, in the dark, either in a refrigerator or at room temperature (2°C to 25°C), but
no higher. Do not freeze.
• The vial of sterilised water that comes with the medicine should also be stored, either in a refrigerator or at room temperature, (up to
25°C, but no higher). Do not freeze.
• Neither the medicine nor the water should be used after the expiry date which is stated as “EXPIRY” on the containers. The expiry
date refers to the last day of that month.
• Do not use any solution if any small bits can be seen in it.
• Once reconstituted, Optivate must be used within one hour.
After injection of the correct dose, dispose of any solution that remains, any used syringes and needles and empty containers. Your
treatment centre will provide a special container (‘sharps box’) for this purpose. Medicines should not be disposed of via wastewater or
6. FURTHER INFORMATION
What Optivate contains
The active substances are human coagulation factor VIII with associated von Willebrand Factor (VWF), the natural stabiliser for factor
VIII. The other ingredients are: sodium chloride, calcium chloride, sodium citrate, polysorbate 20 and trehalose.
Water for injections, sterilised.
What Optivate looks like and contents of the pack
Optivate, in the form of a white or yellow, crumbly powder, comes in quantities of 250 IU (International Units), 500 IU and 1000 IU in
glass vials. These vials are closed with a synthetic rubber stopper under vacuum, held with a tamper-evident cap.
Optivate should only be reconstituted with Sterilised Water for Injections which is supplied with Optivate in plastic ampoules or clear
Marketing Authorisation Holder and Manufacturer
Bio Products Laboratory Limited,
Marketing Authorisation Number
The leaflet was last approved in
For further information or if you have any questions about the use of this product, please contact BPL via the Marketing Department at
the address above or through email@example.com.
Bio Products Laboratory Limited
Dagger Lane, Elstree, Herts., WD6 3BX, U.K.
Tel: +44 (0)20 8957 2200
DATE OF LEAFLET PREPARATION September 2014
1627 Optivate PIL UK 3.indd 5
Source: Medicines and Healthcare Products Regulatory Agency
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.